Publications by authors named "V Vucinic"
Article Synopsis
- Glofitamab, a bispecific antibody targeting CD20 and CD3, shows promise for treating relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) in heavily pretreated patients, with an overall response rate of 47%.
- In a study involving 70 patients in Germany, Austria, and Switzerland, the median number of prior treatments was four, with notable safety concerns including cytokine release syndrome in 40% of cases.
- Important findings indicate that elevated LDH levels predict poorer outcomes, and recent treatment with bendamustine may reduce the efficacy of glofitamab, suggesting careful treatment sequencing is essential.
Article Synopsis
- * Findings indicated that patients' median age at first ASCT has increased, while the use of tandem ASCT decreased, and there were improved survival rates across all age groups, especially older patients.
- * Careful patient selection is crucial for tandem ASCT, as it is less beneficial for those with certain conditions (ISS III and renal impairment), older patients, and those who achieve complete response after initial ASCT.
Article Synopsis
- CAR T-cell therapy shows strong initial results for treating relapsed refractory multiple myeloma, but most patients eventually relapse, often within 5 months.
- In a study of 139 patients who relapsed after CAR T-cell therapy, different salvage therapies were analyzed, revealing that bispecific antibodies, like talquetamab and teclistamab, had the best overall and complete response rates.
- The presence of extramedullary disease at relapse was linked to poorer outcomes, but bispecific antibodies improved survival rates, suggesting they should be the standard treatment for patients relapsing after CAR T-cell therapy.
Introduction: Thiamine-responsive megaloblastic anemia syndrome (TRMA) is a rare autosomal recessive disease with a homozygous or compound-heterozygous mutation in the SLC19A2 gene characterized by megaloblastic anemia, diabetes mellitus (DM), and sensorineural hearing loss with onset in childhood. Folic acid and vitamin B12 in serum are normal with dysplastic erythropoiesis in the bone marrow often mimicking myelodysplastic neoplasms (MDS) as a potential differential diagnosis. Thiamine substitution leads to normalization of anemia, without effects on hearing loss or DM.
View Article and Find Full Text PDF